Kite Pharma (KITE) Announces Positive Topline Data from KTE-C19 ZUMA-1 Study in Aggressive NHL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
BTIG Says Kite Pharma's (KITE) ZUMA-1 Data Doesn't Alter Broader Picture; Affirms at 'Neutral'
September 27, 2016 12:13 PM EDTBTIG affirmed its Neutral rating on Kite Pharma (Nasdaq: KITE) amid ZUMA-1 study results released Monday night.
Analyst Dane Leone commented, We think that the 3-month Complete Response rate of ~33% for the DLBCL cohort is within the 30 40% range expected by investors,... More
Kite Pharma (KITE) to resume trading at 4:30PM ET
September 26, 2016 4:06 PM EDTKite Pharma (NASDAQ: KITE) is expected to resume trading at 4:30PM ET
... MoreKite Pharma (KITE) trading halted with news pending
September 26, 2016 4:00 PM EDTKite Pharma (NASDAQ: KITE) trading halted with news pending.
... MoreKite Pharma (KITE): Reiterating Buy Ahead of ZUMA-1 Study - Stifel
September 22, 2016 7:15 AM EDTStifel analyst, Thomas Shrader, reiterated his Buy rating on shares of Kite Pharma (NASDAQ: KITE) ahead of top-line data from the interim analysis of the ZUMA-1 study, due by the end of the month.
The analyst noted that conversations with clinicians... More
